Similar Articles |
|
Salon.com August 30, 2000 Arthur Allen |
Portrait of a drug czar Gen. Barry McCaffrey drives his government office like a lockstep battalion, but some contend his ruthless schedule and egomaniacal ways are only hurting his effort to bring sanity to America's drug policy. |
Reason Aug/Sep 2001 Jacob Sullum |
Bad Timing "The Drug War Worked Once. It Can Again." So read the headline above William J. Bennett's May 15 defense of drug czar nominee John Walters in The Wall Street Journal... |
The Motley Fool May 26, 2011 Brian Orelli |
Congress Sets Bad Precedent With AVANIR What happened to free markets? |
Salon.com May 12, 2001 Katharine Mieszkowski |
What has Barry McCaffrey been smoking? The former drug czar goes dot-com with an Internet company that charges $1,200 for online drug treatment... |
Salon.com September 1, 2000 Arianna Huffington |
An eerie campaign silence Bush and Gore should tell us where they stand on the ugly $1.3 billion drug war offensive in Colombia that the next president will have to face. |
Chemistry World November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
The Motley Fool July 12, 2010 Ryan McBride |
Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009. |
The Motley Fool February 28, 2011 Brian Orelli |
Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on. |
The Motley Fool February 16, 2010 Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool July 28, 2010 Jordan DiPietro |
3 Biotechs on Your Radar Screen It's not easy keeping track of all the drugs coming in and out of the development pipeline, but if you can stay up to date, you often have an advantage |
Reason March 2001 Michael W. Lynch |
D.C. Downers In which our man in Washington listens to the drug czar babble and learns why we can't afford tax cuts... |
Chemistry World March 2011 |
Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations |
Salon.com July 27, 2000 Daniel Forbes |
Fighting "Cheech & Chong" medicine Did the White House drug office go too far in trying to stop the spread of medical marijuana initiatives? |
Chemistry World July 16, 2010 Matt Wilkinson |
Bittersweet victory for GSK's Avandia GlaxoSmithKline has received a muted 'thumbs up' from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration will allow the UK-based pharma giant to continue selling the drug in the US. |
Salon.com June 30, 2001 Daniel Forbes |
The quiet death of prime-time propaganda With no fanfare, the White House drug office pulls the plug on its controversial program to pay TV networks for putting anti-drug messages in popular shows... |
The Motley Fool January 21, 2011 Brian Orelli |
Mark Your Calendar, Drug Investors Vertex announces that the Food and Drug Administration has accepted its New Drug Application to market telaprevir. |
Reason January 2004 Renee Moilanen |
Just Say No Again The old failures of new and improved anti-drug education |
The Motley Fool May 21, 2010 Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool March 30, 2011 Sean Williams |
China Clamps Down on Drug Manufacturers These drug manufacturers could be feeling a pinch from new Chinese price caps. |
The Motley Fool April 7, 2011 Brian Orelli |
Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market. |
The Motley Fool July 30, 2010 Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
The Motley Fool July 30, 2010 Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
The Motley Fool June 25, 2010 Brian Orelli |
Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review. |
The Motley Fool March 31, 2011 Brian Orelli |
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. |
The Motley Fool December 31, 2010 Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool January 12, 2010 Dayana Yochim |
6 Ways to Score Cheap(er) Drugs Stop overpaying for the pills you have to pop with these simple ways to trim your prescription-drug tab. |
Pharmaceutical Executive April 1, 2011 |
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help. |
The Motley Fool March 4, 2010 Brian Orelli |
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. |
The Motley Fool September 30, 2010 Brian Orelli |
Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers. |
The Motley Fool January 8, 2010 Brian Orelli |
Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands. |
The Motley Fool September 28, 2010 Brian Orelli |
Don't Get Stuck! Invest in Needle-Free Drugs Here's how to make some money off society's general disdain for needles through next-generation drugs. |
The Motley Fool September 24, 2010 Brian Orelli |
Good Deal? Bad Deal? Hard to Tell. Investors are in the dark on Abbott Labs' license of Reata Pharmaceuticals' kidney failure drug bardoxolone for $450 million up front. |
The Motley Fool December 3, 2010 Brian Orelli |
Merck Smartens Up The acquisition of SmartCells looks like an intelligent move. |
The Motley Fool June 29, 2010 Brian Orelli |
The Final Obstacle to Your Drug Company Multibagger The dreaded FDA advisory committee meeting. |
The Motley Fool November 30, 2010 Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
Salon.com January 9, 2001 Arianna Huffington |
The right stuff President-elect Bush should make reform-minded New Mexico Gov. Gary Johnson his drug czar... |
The Motley Fool January 28, 2010 Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool January 29, 2010 Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool September 8, 2010 Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool February 26, 2011 Brian Orelli |
FDA Applications and a Look Ahead It isn't pretty. |
Salon.com August 28, 2000 Ana Arana |
Cleaning up for Clinton The fortress tourist town of Cartagena banned street children and demonstrations on the eve of the president's arrival. |
The Motley Fool March 8, 2010 Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
Salon.com April 20, 2001 Daniel Forbes |
Bush's new drug czar? John Walters, a hard-line drug warrior, is the leading candidate to replace Barry McCaffrey. Advocates say he's a throwback to the bad old days of Bill Bennett... |
The Motley Fool January 25, 2010 Brian Orelli |
No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday. |
The Motley Fool April 22, 2011 Sean Williams |
Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings. |
The Motley Fool December 30, 2010 Brian Orelli |
This NICE Deal Could Foreshadow 2011 Value-based pricing is coming. The only way to encourage lower drug costs is to get the end user to pay the cost directly. |
Salon.com February 22, 2000 Michael Massing |
The elephant in the room Presidential candidates are silent on the failure of the U.S. war on drugs. |
BusinessWeek January 21, 2010 John Carey |
Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes. |
BusinessWeek March 11, 2010 Ellen Gibson |
The Quest to Boost Good Cholesterol Cleveland Clinic's Steven Nissen is again pursuing a drug that will attack plaque by raising HDL. |
Salon.com October 10, 2000 Arthur Allen |
The drug war's Tweedledee Does National Institute on Drug Abuse chief Alan Leshner push propaganda over science in his close coordination with drug czar Barry McCaffrey? |